In Brief: Bradley Pharmaceuticals
Bradley Pharmaceuticals: Payments to Berlex Laboratories deferred as part of a modification of the companies' Nov. 10, 1993 purchase agreement for Berlex's Deconamine line of cold and cough products. Bradley states that it has deferred a $2.67 mil. payment from Dec. 11 to June 30, with a further possible deferment to Aug. 15. The company will pay Berlex monthly interest on the deferred payment at the annual rate of prime plus 4%. The companies also have agreed to defer from Jan. 1, 1996 to Jan. 1, 1998 monthly payments of $84,000. Bradley states that it hopes "to use corporate funds to make the June 30, 1996 payment and to finance the continuation of Bradley's growth, as well as to make a timely second payment of $2.67 mil. due to Berlex in December 1996"...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth